Evidence map›Paper›PMID 16916488›Full record

ReviewCurrent treatment options in oncology2006

Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma.

Jonathan W Friedberg, Arnold S Freedman

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Rituximab in indolent lymphomas.Seminars in hematology · 2010
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jonathan W FriedbergJames P. Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, Box 704, Room 1-4118C, NY 14642, USA. jonathan_friedberg@urmc.rochester.edu
Arnold S Freedman
University of Rochester Medical Center · US

Funding

Monoclonal Antibody Therapy for Follicular LymphomaK23CA102216 · NCI · UNIVERSITY OF ROCHESTER · PI FRIEDBERG, JONATHAN W · 2003 to 2007
$654k
CpG Plus Rituximab Therapy in Follicular LymphomaR21CA103244 · NCI · DANA-FARBER CANCER INSTITUTE · PI FREEDMAN, ARNOLD S. · 2004 to 2005
$567k
NCI NIH HHS CA-102216-01NCI NIH HHS CA-103244
6 · The paper itself

Abstract

Immunomodulatory agents, including cytokines, monoclonal antibodies, and CpG oligonucleotides, have properties that suggest they have the ability to augment rituximab in the treatment of non-Hodgkin's lymphoma. Although several clinical trials have promising results, no randomized trials of reasonable size have been performed to date, limiting the ability to discern whether combinations of immunomodulatory agents with rituximab impact clinical outcome. Until such trials are mature, we do not recommend using these agents in combination outside of the research setting.

Indexed as

Antibodies, MonoclonalAntineoplastic AgentsClinical Trials as TopicHumansImmunologic FactorsLymphoma, Non-HodgkinAntibodies, MonoclonalAntineoplastic AgentsImmunologic Factors

Identifiers

PMID16916488
OpenAlexW2076328072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.